Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11389517 | 0.79 | MEN1 (0.43) | LMNAPKMDRD2PARP1 | |
| SCHEMBL15330711 | 0.79 | LMNA (0.36) | OR51E2KDM4EGAAPOLBCRBN | |
| SCHEMBL13178226 | 0.78 | ALOX5 (0.45) | PKM | |
| SCHEMBL774001 | 0.78 | CRBN (0.40) | OR51E2KDM4EGAAPOLBCRBN | |
| SCHEMBL14107874 | 0.78 | CRBN (0.40) | OR51E2KDM4EGAAPOLBCRBN | |
| SCHEMBL13600572 | 0.75 | LMNA (0.34) | OR51E2KDM4EPOLBCRBNLMNA | |
| SCHEMBL14941658 | 0.74 | LMNA (0.38) | OR51E2KDM4EGAAPOLBCRBN | |
| SCHEMBL9000006 | 0.74 | OR51E2 (0.46) | OR51E2KDM4EGAAPOLBCRBN | |
| SCHEMBL15333289 | 0.74 | LMNA (0.38) | OR51E2KDM4EGAAPOLBCRBN | |
| SCHEMBL12991733 | 0.74 | PAOX (0.46) | KDM4ELMNAPKMHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632829-B2 | Diazepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070249589-A1 | Novel diazepan derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249589-A1 | Novel diazepan derivatives | CCR3, CCR1, CCR10 | OR51E2 399/4885KDM4E 3080/4885GAA 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.